Table 2.
Stimulation site | αPSP decay time (ms) |
αPSP summation | ||
---|---|---|---|---|
−70 mV | −55 mV | −70 mV | −55 mV | |
Quinpirole (n = 9) | ||||
Baseline | 58.9 ± 3.4 | 74.5 ± 3.0 | 1.69 ± 0.09 | 2.26 ± 0.21 |
Drug | 59.3 ± 3.3 | 90.7 ± 3.5* | 1.73 ± 0.08 | 2.99 ± 0.24* |
SKF81297 (n = 9) | ||||
Baseline | 56.8 ± 3.2 | 70.2 ± 3.5 | 1.57 ± 0.07 | 2.11 ± 0.17 |
Drug | 51.8 ± 3.1 | 68.8 ± 3.4 | 1.45 ± 0.09 | 2.20 ± 0.20 |
Sulpiride (n = 6) | ||||
Sulpiride | 56.6 ± 3.0 | 71.8 ± 3.0 | 1.66 ± 0.12 | 2.16 ± 0.23 |
+DA | 51.3 ± 3.1 | 69.1 ± 3.2 | 1.53 ± 0.14 | 1.99 ± 0.23 |
SCH23390 (n = 6) | ||||
SCH23390 | 57.4 ± 3.0 | 73.6 ± 3.1 | 1.56 ± 0.14 | 2.31 ± 0.16 |
+DA | 57.7 ± 2.9 | 89.7 ± 3.2* | 1.65 ± 0.17 | 3.03 ± 0.17 |
Quinpirole, SKF81297, and SCH23390 were administered at 10 μm. Sulpiride was administered at 5 μm. *p < 0.05 with paired t test compared with previous condition at the same Vm.